Parkinsonian syndrome in a dialysis-supported patient receiving high-dose chemotherapy for multiple myeloma.
Fleming
D R
DR
Mangino
P B
PB
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006440:Hemofiltration; D006801:Humans; D007145:Immunoglobulin kappa-Chains; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D051437:Renal Insufficiency / Q000150:complications / Q000628:therapy
D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D007145:Immunoglobulin kappa-Chains; D005047:Etoposide; D003520:Cyclophosphamide